Glass House Brands Inc. announced that its subordinate voting shares have been approved for listing on the New York Stock Exchange. The uplisting, scheduled to commence trading on June 30, 2026, marks a significant developmental milestone for the company and the cannabis industry. This move follows the recent reclassification of medical cannabis to Schedule III, which enabled the listing process.

Kyle Kazan, Co-Founder, Chairman and CEO of Glass House, stated that the listing on the world’s most prestigious stock exchange was not possible prior to the regulatory change. He emphasized the importance of this achievement for the company and its long-term shareholders. The company anticipates that the reclassification will open opportunities such as interstate commerce and the export of medical cannabis to Europe, potentially increasing its addressable market and enhancing profit and cash flow generation.

The subordinate voting shares are expected to begin trading on the NYSE under the symbol GLAS at the opening of trading on June 30, 2026. Until the close of market on June 29, 2026, the shares will continue trading on the OTCQX under the symbol GLASF. Trading on the CBOE under the symbol GLAS.A.U will continue.

Current shareholders are not required to take any action prior to the expected listing. The transition represents a strategic step for Glass House Brands as it positions itself to benefit from favorable pricing dynamics in a potentially expanding market.

Trading Details

Glass House Brands Inc. has announced the acceleration of the expiry date for its Series B, C, and D warrants following a period of sustained share price growth. The company's stock price met the specific trigger conditions outlined in its warrant indentures, closing at or above US$12.00 for 10 trading days within a 15 consecutive trading day period as of June 18, 2026. This move impacts holders of share purchase warrants governed by agreements dated in 2022 and 2023.

The acceleration is based on two separate warrant indentures. The 2022 Warrant Indenture governs the Series B and C Warrants, allowing the company to accelerate expiry if the share price reaches 240% of the current exercise price. Similarly, the 2023 Warrant Indenture governs the Series D Warrants, with an acceleration trigger set at 200% of the current exercise price. In both cases, the threshold price was US$12.00 per share.

Warrant Details and Deadlines

The company has delivered formal notices of acceleration to Odyssey Trust Company, acting as the warrant agent, and to registered warrant holders. The terms of the acceleration specify that the warrants will expire 30 calendar days after the notice was provided. Consequently, warrant holders have a limited window to act on their rights.

Any warrants that remain unexercised after the deadline will automatically expire and will no longer be exercisable. The company emphasized that this action is a direct result of meeting the financial performance metrics stipulated in the contractual agreements with warrant holders.